Afatinib And Necitumumab In Egfr Mutant Nsclc With Acquired Resistance To 1st Or 3rd Generation Egfr Tyrosine Kinase Inhibitors
JOURNAL OF THORACIC ONCOLOGY（2021）
关键词
dual EGFR targeted therapy, phase I results
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要